This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost 2014; 40(5): 571–76. doi: 10.1055/s-0034-1381232.FranchiniMMannucciPMThe history of hemophiliaSemin Thromb Hemost20144055717610.1055/s-0034-1381232Open DOISearch in Google Scholar
Mannucci PM. Miracle of haemophilia drugs: personal views about a few main players. Haemophilia 2018; 24(4): 557–62. doi: 10.1111/hae.13519.MannucciPMMiracle of haemophilia drugs: personal views about a few main playersHaemophilia20182445576210.1111/hae.13519Open DOISearch in Google Scholar
Giangrande PLF, Peyvandi F, O'Mahony B, et al. Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia 2017; 23(3): 370–75. doi: 10.1111/hae.13211.GiangrandePLFPeyvandiFO'MahonyBKreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentratesHaemophilia20172333707510.1111/hae.13211Open DOISearch in Google Scholar
Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160(2): 153–70. doi: 10.1111/bjh.12091.CollinsPWChalmersEHartDPDiagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors OrganizationBr J Haematol201316021537010.1111/bjh.12091Open DOISearch in Google Scholar
Carcao M. Switching from current factor VIII (FVIII) to longer acting FVIII concentrates – what is the real potential benefit? Haemophilia 2015; 21(3): 297–9. doi: 10.1111/hae.12671.CarcaoMSwitching from current factor VIII (FVIII) to longer acting FVIII concentrates – what is the real potential benefit?Haemophilia2015213297910.1111/hae.12671Open DOISearch in Google Scholar
Croteau SE, Neufeld EJ. Transition considerations for extended half-life factor products. Haemophilia 2015; 21(3): 285–8. doi: 10.1111/hae.12683.CroteauSENeufeldEJTransition considerations for extended half-life factor productsHaemophilia2015213285810.1111/hae.12683Open DOISearch in Google Scholar
Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia 2016; 22(4): 487–98. doi: 10.1111/hae.13013.CollinsPChalmersEChowdaryPThe use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDOHaemophilia20162244879810.1111/hae.13013Open DOISearch in Google Scholar
Pollard D, Khair K, Holland M. Switching factor products: nurses’ experience with NovoEight. J Haem Pract 2020; 7(1): 59–69. doi: 10.17225/jhp00156.PollardDKhairKHollandMSwitching factor products: nurses’ experience with NovoEightJ Haem Pract202071596910.17225/jhp00156Open DOISearch in Google Scholar
Santagostino E, Auerswald G, Benson G, et al. Switching treatments in haemophilia: is there a risk of inhibitor development? Eur J Haematol 2015; 94(4): 284–89. doi: 10.1111/ejh.12433.SantagostinoEAuerswaldGBensonGSwitching treatments in haemophilia: is there a risk of inhibitor development?Eur J Haematol20159442848910.1111/ejh.12433Open DOISearch in Google Scholar
Hay CR, Palmer BP, Chalmers EA, et al. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison. Haemophilia 2015; 21(2): 219–26. doi: 10.1111/hae.12563.HayCRPalmerBPChalmersEAThe incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparisonHaemophilia20152122192610.1111/hae.12563Open DOISearch in Google Scholar
Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020 Aug 3. doi: 10.1111/hae.14046. Epub ahead of print.SrivastavaASantagostinoEDougallAWFH guidelines for the management of hemophilia, 3rd editionHaemophilia2020Aug310.1111/hae.14046Epub ahead of printOpen DOISearch in Google Scholar
Pollard D, Khair K, Holland M. Experience of switching to NovoEight: views of people with haemophilia. J Haem Pract 2020; 7(1): 70–77. doi: 10.17225/jhp00157.PollardDKhairKHollandMExperience of switching to NovoEight: views of people with haemophiliaJ Haem Pract202071707710.17225/jhp00157Open DOISearch in Google Scholar
Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Med Decis Making 2015; 35(1): 114–31. doi: 10.1177/0272989x14551638.ShayLALafataJEWhere is the evidence? A systematic review of shared decision making and patient outcomesMed Decis Making20153511143110.1177/0272989x14551638Open DOISearch in Google Scholar
Mantovani LG, Monzini MS, Mannucci PM, et al; Conan Study Group. Differences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experiment. Haemophilia 2005; 11(6): 589–97. doi: 10.1111/j.1365-2516.2005.01159.x.MantovaniLGMonziniMSMannucciPMConan Study GroupDifferences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experimentHaemophilia20051165899710.1111/j.1365-2516.2005.01159.xOpen DOISearch in Google Scholar
von Mackensen S, Kalnins W, Krucker J, et al. Haemophilia patients’ unmet needs and their expectations of the new extended half-life factor concentrates. Haemophilia 2017; 23(4): 566–74. doi: 10.1111/hae.13221.von MackensenSKalninsWKruckerJHaemophilia patients’ unmet needs and their expectations of the new extended half-life factor concentratesHaemophilia20172345667410.1111/hae.13221Open DOISearch in Google Scholar
Khair K, Pollard D, Harrison C, Hook S, O'Driscoll M, Holland M. HOw Patients view Extended half-life products: impressions from real-world experience (The HOPE study). Haemophilia 2019; 25(5): 814–20. doi: 10.1111/hae.13803.KhairKPollardDHarrisonCHookSO'DriscollMHollandMHOw Patients view Extended half-life products: impressions from real-world experience (The HOPE study)Haemophilia20192558142010.1111/hae.13803Open DOISearch in Google Scholar
Smit C. Personal reflections of a patient representative in an appraisal committee. Patient 2015; 8(1): 5–10. doi: 10.1007/s40271-014-0086-8.SmitCPersonal reflections of a patient representative in an appraisal committeePatient20158151010.1007/s40271-014-0086-8Open DOISearch in Google Scholar
